StageZero Announces Third Quarter Analyst and Investor Call
TORONTO, ON / ACCESSWIRE / December 7, 2020 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS) today announced StageZero's...
Month: December 2020
Chemesis International Inc. Announces Placement of VICKI AI-Vending Machine at Reebok LAB in West Hollywood
VANCOUVER, BC / ACCESSWIRE / December 7, 2020 / Chemesis International Inc. (CSE:CSI.U) (OTCQB:CADMF) (FRA:CWAA) (the "Company" or "Chemesis"), announces...
Adastra Announces Processing Agreement with Solargram to Reflect the Company’s Multi-tiered Approach to Increase Sales Revenue
LANGLEY, BC / ACCESSWIRE / December 7, 2020 / Adastra Labs Holdings Ltd. (CSE:XTRX)(FRANKFURT:D2EP) ("Adastra") a Health Canada Licensed cannabis processing...
University of British Columbia Launched as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / December 7, 2020 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
9 Meters Biopharma, Inc. Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome
-Rapid onset and sustained clinical effect following first dose in all 9 patients in total stool output (TSO) volume -Clinically...
Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Multiple Myeloma
-- First Dedicated Clinical Trial of an Anti-CD47 Antibody in Multiple Myeloma ---- At ASH 2020, New Preclinical Data Presented...
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
JATENZO is the first and only FDA-approved oral testosterone replacement therapy of its kind Coverage effective December 1, 2020 on...
Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
Phase 3 trials’ topline data anticipated in the first quarter of 2021 and potential New Drug Application (NDA) submission anticipated...
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
-- Results from the multiple-ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a...
Valneva Announces the Modification of the Conditions of Participation in its Extraordinary General Meeting of December 22, 2020, which will be held as a closed meeting
Saint-Herblain (France), December 7, 2020 – Valneva SE (“Valneva” or “the Company”) announces that due to the current COVID-19 epidemic...
Resonant to Present at LD Micro Main Event
AUSTIN, Texas, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency,...
BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma...
Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference
San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage...
Xtant Medical Announces Expiration of Rights Offering
BELGRADE, Mont., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company...
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast...
Assure Holdings Appoints John Price as Vice President of Finance
DENVER, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider...
SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China
- SELLAS to Potentially Receive Up To $202 Million, Inclusive of $7.5 Million Upfront License Fee and $8 Million Near-term...
BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease
Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise Partnership Focused on Delivering Targeted Therapies for...
Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin
CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna”...